LAGUNA BEACH, Calif. (PRWEB)
January 20, 2020

Michael O’Brien, CADC II, NCAC I, SAP, has released a new book that has just recently achieved the #1 New Release status in the Practice Management category on Amazon.

Addiction Private Practice: The Definitive Guide for Addiction Counselors and Therapists is a comprehensive business plan for addiction counselors and therapists who want to effectively and safely help clients with substance abuse problems in a private office setting.

As one of the most successful independent addiction counselors, O’Brien has shared his secrets to success in his new book with informed strategies, processes, and best practices that will help addiction counselors and therapists take their practice to the next level or refocus their current practice in serving those with substance abuse disorders.

“I wrote this guide to share my success with addiction professionals across the country. Addiction professionals can provide safe and effective help to those suffering from substance use disorders in private practice. Demand has never been higher for these services, and counselors can earn much more than they do in treatment programs,” said Michael O’Brien, CADC I, NCAC I, SAP.

The book offers readers the opportunity to learn about the important components of a successful, ethical, and safe addiction practice while providing crucial advice on how to get started with very minimal start-up capital. O’Brien’s book also provides vital information about how to effectively and ethically market your independent addiction practice.

“Michael O’Brien has not only literally written the book on achieving success in addiction private practice, but he is also living proof that it is possible. His bulletproof addiction practice model is easy to understand and execute, even for those who are not technologically savvy. Any competent counselor can use this book to achieve their desired success. He is selflessly handing his proven strategies to his future competition and propelling the profession forward! This is a huge leap forward for all addiction professionals,” said Sherrie Rager, Ph.D., CADC II, M-RAS, CCDS.

“Addiction Private Practice has been monumental in helping me start my practice. This book lays out step-by-step how to get started, maintain, and continue to thrive in private practice. By following Michael’s strategies, I was able to obtain eight clients in a matter of weeks! His knowledge and strategies work. As a substance abuse counselor, without this information and guidance, I may never have gone into private practice,” added Bryan Vasquez, CAT-C III.

The book is now available in paperback on Amazon. The Kindle, Apple Books, and Google Play versions are in pre-order status at a special price of $9.99 at all major retailers for a limited time. The audiobook will be released within the next two weeks.

Share article on social media or email:

WEST PALM BEACH, Fla. (PRWEB)
January 16, 2020

Ethema Health Corporation (“Ethema” “GRST” or the “Company”), a provider of healthcare services, previously announced an LOI for the acquisition of a majority interest in an addiction treatment company. Efforts are underway to secure financing for the acquisition. Ethema is working with funders the Company is familiar with, having dealt with many over the last several years. There is a high level of interest in the quality of the acquisition and the Company expects to know which group they will be working with by the end of January 2020. Due diligence on the acquisition is on-going and the Company CEO will be doing site visits during the week of January 20, 2020.    

The Company has agreed to vacate its existing West Palm Beach property by January 31, 2020. The Company is continuing to negotiate with a local Florida operation to be able to move its operations but has not yet reached any agreements. As reported earlier, the Company will move its principal office to a location nearby. These processes have begun and are expected to be completed very soon.

The termination of the operation in West Palm Beach will dramatically reduce the negative cash flow of the Company and allow it to focus on cleaning up the debt on the balance sheet as it works towards completing the acquisition. As part of these efforts to reduce debt, the Company is in talks with certain lenders and shareholders of the Company, around the possible sale of the Canadian subsidiary that owns the real estate of the Company’s former operations in Canada. This could help reduce the majority of the debt in one step. The Company is looking for immediate solutions to paying off certain convertible debt, some of which has been converted to equity. The amount and extent of the equity conversions are uncertain and the Company is actively working on short-term replacement financing as a solution.

Additionally, the Company has identified other suitable acquisitions and will be able to add these once a suitable funder has been chosen.

“There is a complete restructuring underway which we expect to stabilize the Company and get it prepared to take on new initiatives in the addiction treatment business. There has been a dramatic shift from the traditional treatment models, that has been driven by the insurance carriers. The changes are still not fully effected, but there are no indications that the addiction problem is getting any better. Addiction and mental health issues are finally receiving the attention they deserve and we will continue to be leaders in providing the best possible care and treatment in the addiction treatment field”, said Shawn Leon CEO of the Company.

About Ethema Health Corporation

Ethema Health Corporation (OTCQB: GRST) operates in the behavioral healthcare space specifically in the treatment of substance use disorders.Ethema developed a unique style of treatment over the last eight years and has had much success with in-patient treatment for adults. Ethema will continue to develop world class programs and techniques for North America. For more information you can visit our website at http://ethemahealth.com.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For information please contact:

Ethema Health Corporation

416-500-0020

shawn@ethemahealth.com

Share article on social media or email:

KIRKLAND, Wash. (PRWEB)
January 15, 2020

Lakeside-Milam Recovery Centers is proud to announce it has become among the first in the nation to receive certification from the American Society of Addiction Medicine (ASAM).

The ASAM Level of Care certification, partnering with the CARF International (CARF) accreditation, provides an independent, comprehensive assessment of an addiction treatment program’s capacity to deliver services consistent with Levels of Care described in The ASAM Criteria. This certification, that compliments the CARF accreditation, will help patients and payers identify those treatment centers that are offering comprehensive, evidence-based care to diagnose and treat the disease of addiction.

“We are proud to have the care we provide certified by the American Society of Addiction Medicine. The opportunity to help patients and their families is an honor and requires trust. Since 1983, we have been a leader in the field due to our understanding of the disease and how to combine medical needs, counseling, and education for effective treatment. ASAM certification is another way for those seeking addiction treatment to know that Lakeside-Milam Recovery Centers offers the highest level of quality care,” says Lakeside-Milam’s President and CEO, Carl Kester.

Certification through ASAM provides a much needed distinction in the addiction treatment industry which has long struggled to establish consistent standards nationwide. The ASAM Criteria is considered the nation’s most respected, comprehensive, and widely used set of standards for providing outcome-oriented care. The certification was developed with over three decades of research and will help payers and patients ensure that the treatment center is held to the highest standard of care.

ABOUT LAKESIDE-MILAM RECOVERY CENTERS:

With over 35 years of experience, Lakeside-Milam has served the Pacific Northwest by providing a full continuum of care. Guided by the book, Under the Influence, by Dr. James Milam and Katherine Ketcham, Lakeside-Milam has helped those struggling with substance abuse by providing quality structure, education, and support. Our goal is for people to recognize that recovery is possible and that they can achieve lasting recovery.

Share article on social media or email:

COLUMBUS, Ohio (PRWEB)
January 13, 2020

BayMark Health Services has announced the opening of MedMark Treatment Centers Columbus Powell, the fifth Ohio location opened in the past year, located at 45 Lazelle Road East on the North side of Columbus. MedMark Columbus Powell will provide medically-supervised, medication-assisted treatment (MAT), counseling and support services for those seeking treatment for opioid use disorder.

“Almost every American has experienced the impact of the opioid crisis in some way and its effects have had a devastating impact in the state of Ohio. In 2017, more than 4,100 residents of Ohio died of an opioid related overdose,” shared David K. White, Ph.D., CEO of BayMark Health Services. “MedMark brings hope and proven treatment services to Columbus and the surrounding area, offering our patients a chance at meaningful, long-term recovery.”

MedMark Treatment Centers are known across the country as providers of comprehensive, individualized treatment for opioid use disorder. Utilizing FDA-approved treatment medications including methadone and buprenorphine, MAT reduces the symptoms of withdrawal and cravings, paving the way for patients to focus on addressing the causes and consequences of their addiction. Additionally, MedMark Columbus Powell will provide addiction education, relapse prevention, lab testing, coordinated care for pregnancy and linkages to community resources to assist patients on their path to recovery.

Chief Operating Officer Frank Baumann added, “We are pleased to be expanding access to a proven treatment model in the Columbus area. MedMark’s medical, clinical and administrative staff offer compassionate, respectful treatment to individuals struggling with addiction, and will no doubt continue to do just that as we welcome patients in our newest facility.”

For more information on MedMark and our services visit: http://www.MedMark.com. To inquire about admission or make a referral contact Nancy Diley-Smith, Treatment Center Director, at 614.502.7646.

About BayMark Health Services:

BayMark Health Services provides medication-assisted treatment to 50,000+ patients in recovery from substance use disorder across the United States and Ontario, Canada. Our outpatient programs deliver medically-supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of opioids, alcohol and other prescription and illicit substances. The BayMark continuum of patient-focused services includes: highly structured opioid treatment programs utilizing methadone or buprenorphine and outpatient buprenorphine treatment programs, both of which incorporate counseling as part of an individualized treatment plan for opioid use disorder. Additionally, ambulatory withdrawal management services with naltrexone therapy, and inpatient detoxification services are offered for a variety of substance use disorders.

Share article on social media or email:

LEWISVILLE, Texas (PRWEB)
January 08, 2020

BayMark Health Services has announced that they are now able to accept Medicare for medication-assisted treatment services at their Opioid Treatment Programs (OTPs) across the country. Coverage for treatment with methadone, buprenorphine and naltrexone, all FDA-approved medications, as well as counseling, began on January 1st. All BayMark branded opioid treatment programs are eligible, including BAART Programs, Health Care Resource Centers, MedMark Treatment Centers and Recovery Services of New Mexico, with the exception of our newest programs who have not yet obtained their CARF-accreditation.

The October 24, 2019 signing of opioid bill H.R. 6, referred to as The SUPPORT for Patients and Communities Act, extended this benefit for Medicare subscribers who may have otherwise lost their ability to stay in treatment when they switched from Medicaid to Medicare or for whom treatment was cost-prohibitive when not covered by their Medicare plan.

“We are extremely pleased that Congress has included Medicare coverage of OTPs in the just-passed opioid package,” said Jason Kletter, PhD, president of BayMark Health Services. “This coverage will, once implemented, provide immediate benefit to the roughly 20,000 Medicare beneficiaries currently receiving treatment in OTPs, as well as create treatment access for the 300,000 beneficiaries with a diagnosis of opioid use disorder,” Dr. Kletter told AT Forum. “In addition, Medicare coverage will likely result in greater coverage of OTP services by commercial health plans, exponentially increasing access to high quality, evidence-based MAT across the country.”

BayMark branded OTPs are known across the country as providers of quality, comprehensive medication-assisted treatment and counseling services. Programs provide addiction education, relapse prevention, lab testing, coordinated care for pregnant patients and linkages to community resources to assist patients on their path to recovery. The BayMark mission is to provide comprehensive medication-assisted treatment for opioid use disorder and other health care services to foster wellness, longevity and socially responsible behavior for the patients we serve.

“BayMark, through our various brands, provides treatment for opioid use disorder. We attempt to match each patient with the best level of care for their individual needs,” shared David K. White, Ph.D., CEO of BayMark Health Services. “Historically, methadone treatment has proven to be the most effective approach to providing affected individuals a real opportunity to recover, in part due to the structure of the OTP. It is great progress for our country that Medicare will now cover methadone treatment, as well as buprenorphine and naltrexone treatment, in the OTP setting. BayMark is happy to be a part of the solution to the opioid epidemic and all initiatives increasing accessibility and affordability of treatment.”

To find a BayMark OTP location near you, visit: http://www.Baymark.com/treatment-locations/.

About BayMark Health Services:

BayMark Health Services provides medication-assisted treatment to more than 56,000 patients in recovery from substance use disorder across the United States and Ontario, Canada. Our outpatient programs deliver medically supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of opioids, alcohol and other prescription and illicit substances. The BayMark continuum of patient-focused services includes: highly structured opioid treatment programs utilizing methadone or buprenorphine and outpatient buprenorphine treatment programs, both of which incorporate counseling as part of an individualized treatment plan for opioid use disorder. Additionally, ambulatory withdrawal management services with naltrexone therapy, and inpatient detoxification services are offered for a variety of substance use disorders.

Share article on social media or email:

CLEVELAND (PRWEB)
January 07, 2020

Attorneys representing America’s most innocent victims in the nation’s prescription opioid crisis took a significant step today within the Multi-District Litigation before Judge Daniel Polster in Cleveland, Ohio by seeking class certification of the guardians responsible for children injured by in-utero exposure to opioids and diagnosed with Neo-Natal Abstinence System or drug dependence.

States, cities, municipalities, hospitals and Native Americans have already gained such class certification status. Those classes do not include guardians of children who were born with Neo-Natal Abstinence Syndrome or drug dependent.

This would be the first-time children diagnosed with Neonatal Abstinence Syndrome, due to the opioid use of their birth mothers, would finally have redress of the lifelong physical and development disabilities and defects these children do and will experience, said Attorney Scott Bickford.

Mr. Bickford, who has argued on behalf of children with NAS for nearly two years before Judge Polster, said his team is being expanded by the legal expertise of Marc Dann, the former Attorney General of Ohio, and class-action experts Kelly and Tom Bilek.

“These children are the most vulnerable and blameless victims of the opioid crisis and will need lifelong medical monitoring and surveillance, as well as medical and social support services,” said Mr. Dann.

“This generation of children is not yet lost but will be without substantial intervention. For two years, their needs have been subordinated to the less urgent needs of government entities which do not have the legal ability to bring claims for these children, do not owe the duty of care to them and will never guarantee their on-going needs are met. Nevertheless, the child’s guardian will surely face and bear the fiduciary responsibility,” Dann added.

The legal filing, with supporting evidence from leading medical experts in the areas of NAS and the scientific relationship between in-utero opioid exposure and birth defects, puts forth studies and testimony to support these arguments, making these main points:

• 
  The nation is vastly undercounting the number of NAS babies, and data shows the number of babies with NAS babies born in the U.S.—now estimated at one every 15 minutes by the Centers for Disease Control– are far greater than the official government count because of flaws in how this information is gathered.
• Babies are sent home from hospitals to guardians with little awareness of what the child and caregiver will face. While physical deformities may be evident when a baby is born, the growing medical science in the NAS area shows opioid exposure in the womb impacts brain size and development which results in long-term developmental effects such delays in walking, talking, hyperactivity, impulsive behaviors, aggression, learning disabilities and other problems which won’t demonstrate until the child ages.
• Governments, schools and other institutions don’t understand the needs of these children because there is no registry of babies with NAS. Thus, families have no roadmap for the challenges ahead. Such a map can only be provided by establishing a registry and providing long-term medical monitoring and research. “This will allow for the program to reach out to the impacted families at the appropriate times,” wrote West Virginia Dr. Charles Werntz III, and also help identify the most hard-hit regions.

Certification of a nationwide class of guardians of NAS children must occur in 2020, the attorneys argue in today’s filing on behalf of families in 34 state class actions. This is underscored by the fact that nationwide, one of every five pregnant women on Medicaid has been prescribed opioids, the filing claims.

“In addition to medical monitoring claims to the guardian, plaintiffs seek to ensure that money needed to pay for testing and epidemiology is actually spent for the direct benefit of children born with NAS. More urgently, intervention and education of doctors and women of child-bearing age is required to immediately stop the possibility of more such births by educating them and the public that opioids cannot be used during pregnancy,” said Mr. Dann.

The link to the filing and supportive statements is here.

Share article on social media or email: